Li, H., Liang, X., Qin, S., Chen, X., Huang, L., Li, Y. (2025). First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0324057